BOULDER, Colo., Oct. 31, 2011 /PRNewswire/ -- Azantis launched today two innovative liposomal products: reduced glutathione and vitamin C. Both oral supplements are formulated in liposomal form to maximize absorption and to minimize side effects. Azantis, a leading phospholipid manufacturer, markets the liposomal products to resellers targeting the health care practitioner channel.
The liposomal glutathione contains 500 mg reduced glutathione per recommended daily dose. These liposomes are highly stable with a very tight particle size range. These features optimize the bioavailability of the glutathione cargo.
Glutathione is the body's most important intracellular sulfur bearing antioxidant, and the body's prime defense against toxins and oxidation. Low glutathione blood levels are commonly associated with poor health.
The vitamin C liposomes are designed to minimize intestinal discomfort, since certain individuals have difficulty tolerating vitamin C therapy at the clinically relevant higher doses. The recommended daily dosage is 1,000 mg vitamin C. The vitamin C, as well as the glutathione liposomal product, is in liquid form.
"Reduced glutathione in liposomal form is superior, because of the maximized absorption. Oral administration of supplemental liposomes, when compared to IV and injections, allows a more even dosing of once or possibly several times per day," said Mickey Schuett, Director of Sales at Azantis Inc. "These products target foremost health care practitioners and resellers that market to these practitioners. The potency of this advanced delivery form is less suitable for the direct to consumer market."
Azantis is a biotech company located in Boulder, Colorado. The company specializes in discovery and extraction of bioactive molecules from sustainable marine and other biomass sources for use in food, nutraceutical, and pharmaceutical products. Azantis' product offerings include omega 3 phospholipids and phospholipid liposomes.
Contact Mickey Schuett, 303-502-2400 or http://www.azantis.com/contact-us/
Copyright©2010 PR Newswire.
All rights reserved